Beyond Remission: How MRD Is Changing AML Care | Episode 2

In the second episode of Hematology CrossTalk, Dr. Gianluca Rotta (Waters™ Biosciences, formerly BD Biosciences) continues the discussion with Prof. Francesco Buccisano (Tor Vergata University of Rome, Italy) and Dr. Vittorio Emanuele Muccio (San Luigi Gonzaga University Hospital, Orbassano, Italy), exploring the evolving role of measurable residual disease (MRD) in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). The conversation looks at how MRD assessment is redefining the definition of complete remission and influencing clinical decision-making. From the laboratory perspective, the experts discuss the challenges of increasing sensitivity, distinguishing normal from abnormal cell populations, and ensuring reproducible results through standardized workflows and expert interpretation. The discussion also looks ahead to the future of MRD assessment, paving the way for next-generation flow cytometry technologies, automated gating and artificial intelligence (AI) supported analysis, while reinforcing the importance of collaboration between laboratory and clinical experts in translating increasingly precise data into patient care. Access the discussion highlights and discover more: https://lp.bd.com/202609-BDB26-EMEA_EN-Cli... All contents are and should be understood as informative in nature and do not discuss, endorse or recommend any specific test, technology, or clinical action. Supported by Waters™ Biosciences (formerly BD Biosciences).